The COVID-19 Serology Studies Workshop: Recommendations and Challenges.


Journal

Immunity
ISSN: 1097-4180
Titre abrégé: Immunity
Pays: United States
ID NLM: 9432918

Informations de publication

Date de publication:
14 07 2020
Historique:
received: 26 05 2020
revised: 11 06 2020
accepted: 16 06 2020
pubmed: 2 7 2020
medline: 24 7 2020
entrez: 2 7 2020
Statut: ppublish

Résumé

The development, validation, and appropriate application of serological assays to detect antibodies to SARS-CoV-2 are essential to determining seroprevalence of this virus in the United States and globally and in guiding government leadership and the private sector on back-to-work policies. An interagency working group of the US Department of Health and Human Services convened a virtual workshop to identify knowledge gaps and key outstanding scientific issues and to develop strategies to fill them. Key outcomes of the workshop included recommendations for (1) advancing serology assays as a tool to better understand SARS-CoV-2 infection and (2) conducting crucial serology field studies to advance an understanding of immunity to SARS-CoV-2, leading to protection and duration of protection, including the correlation between serological test results and risk of reinfection.

Identifiants

pubmed: 32610080
pii: S1074-7613(20)30267-3
doi: 10.1016/j.immuni.2020.06.012
pmc: PMC7309808
pii:
doi:

Substances chimiques

Antibodies, Viral 0

Types de publication

Clinical Conference Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-5

Informations de copyright

Copyright © 2020.

Références

Nat Med. 2020 Jul;26(7):1033-1036
pubmed: 32398876
J Clin Microbiol. 2020 Jul 23;58(8):
pubmed: 32381641
Curr Protoc Microbiol. 2020 Jun;57(1):e100
pubmed: 32302069
Nat Med. 2013 Oct;19(10):1305-12
pubmed: 24056771
Nat Commun. 2020 Sep 17;11(1):4704
pubmed: 32943637
Lancet Microbe. 2020 Nov;1(7):e283-e289
pubmed: 33015652

Auteurs

Andrea M Lerner (AM)

Office of the Director, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. Electronic address: andrea.lerner@nih.gov.

Robert W Eisinger (RW)

Office of the Director, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. Electronic address: robert.eisinger@nih.gov.

Douglas R Lowy (DR)

Office of the Director, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

Lyle R Petersen (LR)

Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, Fort Collins, CO 80521, USA.

Rosemary Humes (R)

Biomedical Advanced Research and Development Authority, US Department of Health and Human Services, Washington, DC 20201, USA.

Matthew Hepburn (M)

Defense Advanced Research Projects Agency, US Department of Defense, Arlington, VA 22203, USA.

M Cristina Cassetti (MC)

Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. Electronic address: CCassetti@niaid.nih.gov.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH